메뉴 건너뛰기




Volumn 66, Issue , 2015, Pages 161-176

Cardiovascular disease in adult survivors of childhood cancer

Author keywords

etiology; prevention; screening; treatment

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; PROTEIN TYROSINE KINASE INHIBITOR; RAZOXANE; TRASTUZUMAB; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; CARDIOTONIC AGENT;

EID: 84921354929     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-070213-054849     Document Type: Article
Times cited : (106)

References (103)
  • 1
    • 0003964363 scopus 로고    scopus 로고
    • American Cancer Society. Atlanta: Am. Cancer Soc. 2013
    • American Cancer Society. 2013. Cancer Facts & Figures 2013. Atlanta: Am. Cancer Soc.
    • (2013) Cancer Facts & Figures
  • 3
    • 0026031848 scopus 로고
    • Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood
    • Lipshultz SE, Colan SD, Gelber RD, et al. 1991. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 324:808-15
    • (1991) N. Engl. J. Med. , vol.324 , pp. 808-815
    • Lipshultz, S.E.1    Colan, S.D.2    Gelber, R.D.3
  • 4
    • 84870055817 scopus 로고    scopus 로고
    • Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort
    • Mulrooney DA, YeazelMW, KawashimaT, et al. 2009. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606
    • (2009) BMJ , vol.339 , pp. b4606
    • Mulrooney, D.A.1    Yeazel, M.W.2    Kawashima, T.3
  • 5
    • 33749599695 scopus 로고    scopus 로고
    • Chronic health conditions in adult survivors of childhood cancer
    • Oeffinger KC, Mertens AC, Sklar CA, et al. 2006. Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med. 355:1572-82
    • (2006) N. Engl. J. Med. , vol.355 , pp. 1572-1582
    • Oeffinger, K.C.1    Mertens, A.C.2    Sklar, C.A.3
  • 6
    • 53249111431 scopus 로고    scopus 로고
    • Cause-specific late mortality among 5-year survivors of childhood cancer: The Childhood Cancer Survivor Study
    • Mertens AC, Liu Q, Neglia JP, et al. 2008. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J. Natl. Cancer Inst. 100:1368-79
    • (2008) J. Natl. Cancer Inst. , vol.100 , pp. 1368-1379
    • Mertens, A.C.1    Liu, Q.2    Neglia, J.P.3
  • 7
    • 77950464739 scopus 로고    scopus 로고
    • Cardiotoxicity after childhood cancer: Beginning with the end in mind
    • Lipshultz SE, Adams MJ. 2010. Cardiotoxicity after childhood cancer: beginning with the end in mind. J. Clin. Oncol. 28:1276-81
    • (2010) J. Clin. Oncol. , vol.28 , pp. 1276-1281
    • Lipshultz, S.E.1    Adams, M.J.2
  • 8
    • 77950498795 scopus 로고    scopus 로고
    • Role of cancer treatment in long-Term overall and cardiovascular mortality after childhood cancer
    • Tukenova M, Guibout C, Oberlin O, et al. 2010. Role of cancer treatment in long-Term overall and cardiovascular mortality after childhood cancer. J. Clin. Oncol. 28:1308-15
    • (2010) J. Clin. Oncol. , vol.28 , pp. 1308-1315
    • Tukenova, M.1    Guibout, C.2    Oberlin, O.3
  • 9
    • 0035398020 scopus 로고    scopus 로고
    • Late mortality experience in five-year survivors of childhood and adolescent cancer: The Childhood Cancer Survivor Study
    • Mertens AC, Yasui Y, Neglia JP, et al. 2001. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J. Clin. Oncol. 19:3163-72
    • (2001) J. Clin. Oncol. , vol.19 , pp. 3163-3172
    • Mertens, A.C.1    Yasui, Y.2    Neglia, J.P.3
  • 10
    • 77954582454 scopus 로고    scopus 로고
    • Long-Term cause-specific mortality among survivors of childhood cancer
    • Reulen RC, Winter DL, Frobisher C, et al. 2010. Long-Term cause-specific mortality among survivors of childhood cancer. JAMA 304:172-79
    • (2010) JAMA , vol.304 , pp. 172-179
    • Reulen, R.C.1    Winter, D.L.2    Frobisher, C.3
  • 11
    • 0031894189 scopus 로고    scopus 로고
    • Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia
    • Nysom K, Holm K, Lipsitz SR, et al. 1998. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J. Clin. Oncol. 16:545-50
    • (1998) J. Clin. Oncol. , vol.16 , pp. 545-550
    • Nysom, K.1    Holm, K.2    Lipsitz, S.R.3
  • 12
    • 18444416815 scopus 로고    scopus 로고
    • Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia
    • Lipshultz SE, Lipsitz SR, Sallan SE, et al. 2005. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J. Clin. Oncol. 23:2629-36
    • (2005) J. Clin. Oncol. , vol.23 , pp. 2629-2636
    • Lipshultz, S.E.1    Lipsitz, S.R.2    Sallan, S.E.3
  • 13
    • 0035990041 scopus 로고    scopus 로고
    • Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: A systematic review
    • Kremer LC, van der Pal HJ, OffringaM, et al. 2002. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann. Oncol. 13:819-29
    • (2002) Ann. Oncol. , vol.13 , pp. 819-829
    • Kremer, L.C.1    Van Der Pal, H.J.2    Offringa, M.3
  • 14
    • 18244372155 scopus 로고    scopus 로고
    • Pathophysiology of anthracycline-And radiation-Associated cardiomyopathies: Implications for screening and prevention
    • Adams MJ, Lipshultz SE. 2005. Pathophysiology of anthracycline-And radiation-Associated cardiomyopathies: implications for screening and prevention. Pediatr. Blood Cancer 44:600-6
    • (2005) Pediatr. Blood Cancer , vol.44 , pp. 600-606
    • Adams, M.J.1    Lipshultz, S.E.2
  • 15
    • 84921406669 scopus 로고    scopus 로고
    • Effect of dexrazoxane on impaired mitochondrial structure and function in doxorubicin-Treated childhood ALL survivors
    • Abstr.) Suppl.
    • Lipshultz SE, Miller TL, GerschensonM, et al. 2012. Effect of dexrazoxane on impaired mitochondrial structure and function in doxorubicin-Treated childhood ALL survivors. J. Clin. Oncol. 30(Suppl.):9530 (Abstr.)
    • (2012) J. Clin. Oncol. , vol.30 , pp. 9530
    • Lipshultz, S.E.1    Miller, T.L.2    Gerschenson, M.3
  • 16
    • 14944358230 scopus 로고    scopus 로고
    • Clinical significance of cyclophosphamide-induced cardiotoxicity
    • Taniguchi I. 2005. Clinical significance of cyclophosphamide-induced cardiotoxicity. Intern.Med. 44:89-90
    • (2005) Intern.Med. , vol.44 , pp. 89-90
    • Taniguchi, I.1
  • 17
    • 34347395733 scopus 로고    scopus 로고
    • Trastuzumab-mechanism of action and use in clinical practice
    • Hudis CA. 2007. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357:39-51
    • (2007) N. Engl. J. Med. , vol.357 , pp. 39-51
    • Hudis, C.A.1
  • 18
    • 52049104951 scopus 로고    scopus 로고
    • A phase i study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors
    • Albanell J, Montagut C, Jones ET, et al. 2008. A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. Clin. Cancer Res. 14:2726-31
    • (2008) Clin. Cancer Res. , vol.14 , pp. 2726-2731
    • Albanell, J.1    Montagut, C.2    Jones, E.T.3
  • 19
    • 74049164266 scopus 로고    scopus 로고
    • The vulnerability of the heart as a pluricellular paracrine organ: Lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy
    • De Keulenaer GW, Doggen K, Lemmens K. 2010. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ. Res. 106:35-46
    • (2010) Circ. Res. , vol.106 , pp. 35-46
    • De Keulenaer, G.W.1    Doggen, K.2    Lemmens, K.3
  • 20
    • 84866060182 scopus 로고    scopus 로고
    • Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study
    • Bowles EJ, Wellman R, Feigelson HS, et al. 2012. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J. Natl. Cancer Inst. 104:1293-305
    • (2012) J. Natl. Cancer Inst. , vol.104 , pp. 1293-1305
    • Bowles, E.J.1    Wellman, R.2    Feigelson, H.S.3
  • 21
    • 32144448027 scopus 로고    scopus 로고
    • Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment
    • Ewer MS, Vooletich MT, Durand JB, et al. 2005. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol. 23:7820-26
    • (2005) J. Clin. Oncol. , vol.23 , pp. 7820-7826
    • Ewer, M.S.1    Vooletich, M.T.2    Durand, J.B.3
  • 22
    • 84864044404 scopus 로고    scopus 로고
    • Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: A report from the Children's Oncology Group
    • Ebb D, Meyers P, Grier H, et al. 2012. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the Children's Oncology Group. J. Clin. Oncol. 30:2545-51
    • (2012) J. Clin. Oncol. , vol.30 , pp. 2545-2551
    • Ebb, D.1    Meyers, P.2    Grier, H.3
  • 23
    • 44949253343 scopus 로고    scopus 로고
    • Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials
    • Perez EA, Koehler M, Byrne J, et al. 2008. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin. Proc. 83:679-86
    • (2008) Mayo Clin. Proc. , vol.83 , pp. 679-686
    • Perez, E.A.1    Koehler, M.2    Byrne, J.3
  • 24
    • 77957961667 scopus 로고    scopus 로고
    • Phase i trial of lapatinib in children with refractory CNS malignancies: A Pediatric Brain Tumor Consortium study
    • FouladiM, Stewart CF, Blaney SM, et al. 2010. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J. Clin. Oncol. 28:4221-27
    • (2010) J. Clin. Oncol. , vol.28 , pp. 4221-4227
    • Fouladi, M.1    Stewart, C.F.2    Blaney, S.M.3
  • 25
    • 79955040838 scopus 로고    scopus 로고
    • Treatment of pediatric chronic myeloid leukemia in the year 2010: Use of tyrosine kinase inhibitors and stem-cell transplantation
    • Suttorp M, Millot F. 2010. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematol. Am. Soc. Hematol. Educ. Program 2010:368-76
    • (2010) Hematol. Am. Soc. Hematol. Educ. Program , vol.2010 , pp. 368-376
    • Suttorp, M.1    Millot, F.2
  • 26
    • 33746845181 scopus 로고    scopus 로고
    • Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
    • Kerkela R, Grazette L, Yacobi R, et al. 2006. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12:908-16
    • (2006) Nat. Med. , vol.12 , pp. 908-916
    • Kerkela, R.1    Grazette, L.2    Yacobi, R.3
  • 27
    • 34548030470 scopus 로고    scopus 로고
    • Congestive heart failure is a rare event in patients receiving imatinib therapy
    • Atallah E, Durand JB, Kantarjian H, Cortes J. 2007. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 110:1233-37
    • (2007) Blood , vol.110 , pp. 1233-1237
    • Atallah, E.1    Durand, J.B.2    Kantarjian, H.3    Cortes, J.4
  • 28
    • 37549041711 scopus 로고    scopus 로고
    • A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study
    • Bond M, Bernstein ML, Pappo A, et al. 2008. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr. Blood Cancer 50:254-58
    • (2008) Pediatr. Blood Cancer , vol.50 , pp. 254-258
    • Bond, M.1    Bernstein, M.L.2    Pappo, A.3
  • 29
    • 70449711127 scopus 로고    scopus 로고
    • Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children's Oncology Group study
    • Schultz KR, Bowman WP, Aledo A, et al. 2009. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J. Clin. Oncol. 27:5175-81
    • (2009) J. Clin. Oncol. , vol.27 , pp. 5175-5181
    • Schultz, K.R.1    Bowman, W.P.2    Aledo, A.3
  • 30
    • 82355169061 scopus 로고    scopus 로고
    • A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat
    • Herman EH, Knapton A, Rosen E, et al. 2011. A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat. Toxicol. Pathol. 39:1091-106
    • (2011) Toxicol. Pathol. , vol.39 , pp. 1091-1106
    • Herman, E.H.1    Knapton, A.2    Rosen, E.3
  • 31
    • 84873529136 scopus 로고    scopus 로고
    • Dasatinib, nilotinib and standard-dose imatinib for the firstline treatment of chronic myeloid leukaemia: Systematic reviews and economic analyses
    • Pavey T, Hoyle M, Ciani O, et al. 2012. Dasatinib, nilotinib and standard-dose imatinib for the firstline treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. Health Technol. Assess. 16(42):1-277
    • (2012) Health Technol. Assess. , vol.16 , Issue.42 , pp. 1-277
    • Pavey, T.1    Hoyle, M.2    Ciani, O.3
  • 33
    • 84883741352 scopus 로고    scopus 로고
    • Nilotinib treatment-Associated accelerated atherosclerosis: When is the risk justified?
    • Tefferi A. 2013. Nilotinib treatment-Associated accelerated atherosclerosis: When is the risk justified?. Leukemia 27:1939-40
    • (2013) Leukemia , vol.27 , pp. 1939-1940
    • Tefferi, A.1
  • 34
    • 84887076805 scopus 로고    scopus 로고
    • Cancer-drug discovery and cardiovascular surveillance
    • Groarke JD, Cheng S, Moslehi J. 2013. Cancer-drug discovery and cardiovascular surveillance. N. Engl. J. Med. 369:1779-81
    • (2013) N. Engl. J. Med. , vol.369 , pp. 1779-1781
    • Groarke, J.D.1    Cheng, S.2    Moslehi, J.3
  • 35
    • 84875886935 scopus 로고    scopus 로고
    • Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives
    • Bair SM, ChoueiriTK, Moslehi J. 2013. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc. Med. 23:104-13
    • (2013) Trends Cardiovasc. Med. , vol.23 , pp. 104-113
    • Bair, S.M.1    Choueiri, T.K.2    Moslehi, J.3
  • 36
    • 79955767772 scopus 로고    scopus 로고
    • Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib
    • Rini BI, Cohen DP, LuDR, et al. 2011. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl. Cancer Inst. 103:763-73
    • (2011) J. Natl. Cancer Inst. , vol.103 , pp. 763-773
    • Rini, B.I.1    Cohen, D.P.2    Lu, D.R.3
  • 37
    • 36849023013 scopus 로고    scopus 로고
    • Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
    • Chu TF, Rupnick MA, Kerkela R, et al. 2007. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011-19
    • (2007) Lancet , vol.370 , pp. 2011-2019
    • Chu, T.F.1    Rupnick, M.A.2    Kerkela, R.3
  • 38
    • 50849094516 scopus 로고    scopus 로고
    • Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
    • Telli ML, Witteles RM, Fisher GA, Srinivas S. 2008. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann. Oncol. 19:1613-18
    • (2008) Ann. Oncol. , vol.19 , pp. 1613-1618
    • Telli, M.L.1    Witteles, R.M.2    Fisher, G.A.3    Srinivas, S.4
  • 39
    • 55949123335 scopus 로고    scopus 로고
    • Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma
    • Schmidinger M, Zielinski CC, Vogl UM, et al. 2008. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26:5204-12
    • (2008) J. Clin. Oncol. , vol.26 , pp. 5204-5212
    • Schmidinger, M.1    Zielinski, C.C.2    Vogl, U.M.3
  • 40
    • 79960983264 scopus 로고    scopus 로고
    • Phase i and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: A Children's Oncology Group study
    • Dubois SG, Shusterman S, Ingle AM, et al. 2011. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Clin. Cancer Res. 17:5113-22
    • (2011) Clin. Cancer Res. , vol.17 , pp. 5113-5122
    • Dubois, S.G.1    Shusterman, S.2    Ingle, A.M.3
  • 41
    • 80052017961 scopus 로고    scopus 로고
    • Phase i pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia
    • Inaba H, Rubnitz JE, Coustan-Smith E, et al. 2011. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J. Clin. Oncol. 29:3293-300
    • (2011) J. Clin. Oncol. , vol.29 , pp. 3293-3300
    • Inaba, H.1    Rubnitz, J.E.2    Coustan-Smith, E.3
  • 42
    • 84868543745 scopus 로고    scopus 로고
    • A phase i trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: A Children's Oncology Group Phase i Consortium report
    • Widemann BC, Kim A, Fox E, et al. 2012. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin. Cancer Res. 18:6011-22
    • (2012) Clin. Cancer Res. , vol.18 , pp. 6011-6022
    • Widemann, B.C.1    Kim, A.2    Fox, E.3
  • 43
    • 0026513214 scopus 로고
    • Coronary artery disease mortality in patients treated for Hodgkin's disease
    • Boivin JF, Hutchison GB, Lubin JH, Mauch P. 1992. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 69:1241-47
    • (1992) Cancer , vol.69 , pp. 1241-1247
    • Boivin, J.F.1    Hutchison, G.B.2    Lubin, J.H.3    Mauch, P.4
  • 44
    • 4143078308 scopus 로고    scopus 로고
    • Cardiovascular status in long-Term survivors of Hodgkin's disease treated with chest radiotherapy
    • AdamsMJ, Lipsitz SR, Colan SD, et al. 2004. Cardiovascular status in long-Term survivors of Hodgkin's disease treated with chest radiotherapy. J. Clin. Oncol. 22:3139-48
    • (2004) J. Clin. Oncol. , vol.22 , pp. 3139-3148
    • Adams, M.J.1    Lipsitz, S.R.2    Colan, S.D.3
  • 45
    • 84879504038 scopus 로고    scopus 로고
    • Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: An analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study
    • Landy DC, Miller TL, Lipsitz SR, et al. 2013. Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study. Pediatr. Cardiol. 34:826-34
    • (2013) Pediatr. Cardiol. , vol.34 , pp. 826-834
    • Landy, D.C.1    Miller, T.L.2    Lipsitz, S.R.3
  • 46
    • 84861763781 scopus 로고    scopus 로고
    • Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy
    • Lipshultz SE, Landy DC, Lopez-Mitnik G, et al. 2012. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J. Clin. Oncol. 30:1050-57
    • (2012) J. Clin. Oncol. , vol.30 , pp. 1050-1057
    • Lipshultz, S.E.1    Landy, D.C.2    Lopez-Mitnik, G.3
  • 47
    • 41149115636 scopus 로고    scopus 로고
    • Anthracycline associated cardiotoxicity in survivors of childhood cancer
    • Lipshultz SE, Alvarez JA, Scully RE. 2008. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94:525-33
    • (2008) Heart , vol.94 , pp. 525-533
    • Lipshultz, S.E.1    Alvarez, J.A.2    Scully, R.E.3
  • 48
    • 0035155497 scopus 로고    scopus 로고
    • Anthracycline-induced clinical heart failure in a cohort of 607 children: Long-Term follow-up study
    • Kremer LC, van Dalen EC, Offringa M, et al. 2001. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-Term follow-up study. J. Clin. Oncol. 19:191-96
    • (2001) J. Clin. Oncol. , vol.19 , pp. 191-196
    • Kremer, L.C.1    Van Dalen, E.C.2    Offringa, M.3
  • 49
    • 79953732943 scopus 로고    scopus 로고
    • Anthracycline-Associated cardiotoxicity in survivors of childhood cancer
    • TrachtenbergBH, LandyDC, Franco VI, et al. 2011. Anthracycline-Associated cardiotoxicity in survivors of childhood cancer. Pediatr. Cardiol. 32:342-53
    • (2011) Pediatr. Cardiol. , vol.32 , pp. 342-353
    • Trachtenberg, B.H.1    Landy, D.C.2    Franco, V.I.3
  • 50
    • 84876494771 scopus 로고    scopus 로고
    • Ethnic group differences in cardiometabolic disease risk factors independent of body mass index among American youth
    • Messiah SE, Arheart KL, Lopez-Mitnik G, et al. 2013. Ethnic group differences in cardiometabolic disease risk factors independent of body mass index among American youth. Obesity 21:424-28
    • (2013) Obesity , vol.21 , pp. 424-428
    • Messiah, S.E.1    Arheart, K.L.2    Lopez-Mitnik, G.3
  • 51
    • 84856509803 scopus 로고    scopus 로고
    • Aggregating traditional cardiovascular disease risk factors to assess the cardiometabolic health of childhood cancer survivors: An analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study
    • Landy DC, Miller TL, Lopez-Mitnik G, et al. 2012. Aggregating traditional cardiovascular disease risk factors to assess the cardiometabolic health of childhood cancer survivors: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study. Am. Heart J. 163:295-301.e2
    • (2012) Am. Heart J. , vol.163 , pp. 295-295e2
    • Landy, D.C.1    Miller, T.L.2    Lopez-Mitnik, G.3
  • 52
    • 65649091719 scopus 로고    scopus 로고
    • Predictors of inactive lifestyle among adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study
    • Ness KK, Leisenring WM, Huang S, et al. 2009. Predictors of inactive lifestyle among adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer 115:1984-94
    • (2009) Cancer , vol.115 , pp. 1984-1994
    • Ness, K.K.1    Leisenring, W.M.2    Huang, S.3
  • 53
    • 84873714954 scopus 로고    scopus 로고
    • Exercise capacity in long-Term survivors of pediatric cancer: An analysis from the Cardiac Risk Factors inChildhood Cancer Survivors Study
    • Miller AM, Lopez-Mitnik G, Somarriba G, et al. 2013. Exercise capacity in long-Term survivors of pediatric cancer: an analysis from the Cardiac Risk Factors inChildhood Cancer Survivors Study. Pediatr. Blood Cancer 60:663-68
    • (2013) Pediatr. Blood Cancer , vol.60 , pp. 663-668
    • Miller, A.M.1    Lopez-Mitnik, G.2    Somarriba, G.3
  • 54
    • 84884908105 scopus 로고    scopus 로고
    • Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-Treated survivors of childhood high-risk leukemia
    • Lipshultz SE, Lipsitz SR, Kutok JL, et al. 2013. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-Treated survivors of childhood high-risk leukemia. Cancer 119:3555-62
    • (2013) Cancer , vol.119 , pp. 3555-3562
    • Lipshultz, S.E.1    Lipsitz, S.R.2    Kutok, J.L.3
  • 55
    • 46049104446 scopus 로고    scopus 로고
    • Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer
    • Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, et al. 2008. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112:2789-95
    • (2008) Cancer , vol.112 , pp. 2789-2795
    • Blanco, J.G.1    Leisenring, W.M.2    Gonzalez-Covarrubias, V.M.3
  • 56
    • 81855225220 scopus 로고    scopus 로고
    • Anthracycline-related cardiomyopathy after childhood cancer: Role of polymorphisms in carbonyl reductase genes-A report from the Children's Oncology Group
    • Blanco JG, Sun CL, Landier W, et al. 2012. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes-A report from the Children's Oncology Group. J. Clin. Oncol. 30:1415-21
    • (2012) J. Clin. Oncol. , vol.30 , pp. 1415-1421
    • Blanco, J.G.1    Sun, C.L.2    Landier, W.3
  • 57
    • 84863001655 scopus 로고    scopus 로고
    • Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children
    • Visscher H, Ross CJ, Rassekh SR, et al. 2012. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J. Clin. Oncol. 30:1422-28
    • (2012) J. Clin. Oncol. , vol.30 , pp. 1422-1428
    • Visscher, H.1    Ross, C.J.2    Rassekh, S.R.3
  • 58
    • 84879219119 scopus 로고    scopus 로고
    • Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children
    • VisscherH, Ross CJ, Rassekh SR, et al. 2013. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr. Blood Cancer 60:1375-81
    • (2013) Pediatr. Blood Cancer , vol.60 , pp. 1375-1381
    • Visscher, H.1    Ross, C.J.2    Rassekh, S.R.3
  • 59
    • 0141816698 scopus 로고    scopus 로고
    • Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin
    • Miranda CJ, Makui H, Soares RJ, et al. 2003. Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood 102:2574-80
    • (2003) Blood , vol.102 , pp. 2574-2580
    • Miranda, C.J.1    Makui, H.2    Soares, R.J.3
  • 60
    • 0030071262 scopus 로고    scopus 로고
    • Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children
    • Lipshultz SE. 1996. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J. Clin. Oncol. 14:328-31
    • (1996) J. Clin. Oncol. , vol.14 , pp. 328-331
    • Lipshultz, S.E.1
  • 61
    • 77957355941 scopus 로고    scopus 로고
    • Assessment of dexrazoxane as a cardioprotectant in doxorubicin-Treated children with high-risk acute lymphoblastic leukaemia: Long-Term follow-up of a prospective, randomized, multicentre trial
    • Lipshultz SE, Scully RE, Lipsitz SR, et al. 2010. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-Treated children with high-risk acute lymphoblastic leukaemia: long-Term follow-up of a prospective, randomized, multicentre trial. Lancet Oncol. 11:950-61
    • (2010) Lancet Oncol. , vol.11 , pp. 950-961
    • Lipshultz, S.E.1    Scully, R.E.2    Lipsitz, S.R.3
  • 62
    • 9044233260 scopus 로고    scopus 로고
    • Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin
    • Wexler LH, Andrich MP, Venzon D, et al. 1996. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J. Clin. Oncol. 14:362-72
    • (1996) J. Clin. Oncol. 62 , vol.14 , pp. 362-372
    • Wexler, L.H.1    Andrich, M.P.2    Venzon, D.3
  • 64
    • 3042850886 scopus 로고    scopus 로고
    • The effect of dexrazoxane on myocardial injury in doxorubicin-Treated children with acute lymphoblastic leukemia
    • Lipshultz SE, Rifai N, Dalton VM, et al. 2004. The effect of dexrazoxane on myocardial injury in doxorubicin-Treated children with acute lymphoblastic leukemia. N. Engl. J. Med. 351:145-53
    • (2004) N. Engl. J. Med. , vol.351 , pp. 145-153
    • Lipshultz, S.E.1    Rifai, N.2    Dalton, V.M.3
  • 65
    • 84921414996 scopus 로고    scopus 로고
    • Cardioprotection and safety of dexrazoxane (DRZ) in children treated for newly diagnosedT-cell acute lymphoblastic leukemia (T-ALL) or advanced stage lymphoblastic leukemia (T-LL)
    • Abstr.) Suppl.
    • Asselin B, DevidasM, ZhouT, et al. 2012. Cardioprotection and safety of dexrazoxane (DRZ) in children treated for newly diagnosedT-cell acute lymphoblastic leukemia (T-ALL) or advanced stage lymphoblastic leukemia (T-LL). J. Clin. Oncol. 30(Suppl.):9504 (Abstr.)
    • (2012) J. Clin. Oncol. , vol.30 , pp. 9504
    • Asselin, B.1    Devidas, M.2    Zhou, T.3
  • 66
    • 84907485198 scopus 로고    scopus 로고
    • The effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-Treated patients with osteosarcoma (OS)
    • Abstr.) Suppl.
    • Kopp LM, Bernstein ML, Schwartz CL, et al. 2012. The effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-Treated patients with osteosarcoma (OS). J. Clin. Oncol. 30(Suppl.):9503 (Abstr.)
    • (2012) J. Clin. Oncol. , vol.30 , pp. 9503
    • Kopp, L.M.1    Bernstein, M.L.2    Schwartz, C.L.3
  • 67
    • 84873722765 scopus 로고    scopus 로고
    • Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: Analysis of a national cohort of patients in the Pediatric Health Information Systems database
    • Walker DM, Fisher BT, Seif AE, et al. 2013. Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database. Pediatr. Blood Cancer 60:616-20
    • (2013) Pediatr. Blood Cancer , vol.60 , pp. 616-620
    • Walker, D.M.1    Fisher, B.T.2    Seif, A.E.3
  • 68
    • 34547677730 scopus 로고    scopus 로고
    • Dexrazoxane-Associated risk for secondary malignancies in pediatric Hodgkin's disease: A claim without compelling evidence
    • author reply 3180
    • Lipshultz SE, Lipsitz SR, Orav EJ. 2007. Dexrazoxane-Associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence. J. Clin. Oncol. 25:3179; author reply 3180
    • (2007) J. Clin. Oncol. , vol.25 , pp. 3179
    • Lipshultz, S.E.1    Lipsitz, S.R.2    Orav, E.J.3
  • 69
    • 35648964243 scopus 로고    scopus 로고
    • Dexrazoxane-Associated risk for secondary malignancies in pediatric Hodgkin's disease: A claim without evidence
    • 4689-90; author reply
    • Hellmann K. 2007. Dexrazoxane-Associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without evidence. J. Clin. Oncol. 25:4689-90; author reply 90-91
    • (2007) J. Clin. Oncol. , vol.25 , pp. 90-91
    • Hellmann, K.1
  • 70
    • 33845402341 scopus 로고    scopus 로고
    • Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition
    • Cardinale D, Colombo A, Sandri MT, et al. 2006. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474-81
    • (2006) Circulation , vol.114 , pp. 2474-2481
    • Cardinale, D.1    Colombo, A.2    Sandri, M.T.3
  • 71
    • 41949096690 scopus 로고    scopus 로고
    • Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane
    • Barry EV, Vrooman LM, Dahlberg SE, et al. 2008. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J. Clin. Oncol. 26:1106-11
    • (2008) J. Clin. Oncol. , vol.26 , pp. 1106-1111
    • Barry, E.V.1    Vrooman, L.M.2    Dahlberg, S.E.3
  • 72
    • 84921406668 scopus 로고    scopus 로고
    • Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence
    • In press. doi: 101016/j.ppedcard.2014.09.007
    • Lipshultz SE, Franco VI, Sallan SE, et al. 2014. Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: an update of the evidence. Prog. Pediatr. Cardiol. In press. doi: 101016/j.ppedcard.2014.09.007
    • (2014) Prog. Pediatr. Cardiol
    • Lipshultz, S.E.1    Franco, V.I.2    Sallan, S.E.3
  • 73
    • 79957557043 scopus 로고    scopus 로고
    • The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium
    • Vrooman LM, Neuberg DS, Stevenson KE, et al. 2011. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur. J. Cancer 47:1373-79
    • (2011) Eur. J. Cancer , vol.47 , pp. 1373-1379
    • Vrooman, L.M.1    Neuberg, D.S.2    Stevenson, K.E.3
  • 74
    • 76749108960 scopus 로고    scopus 로고
    • Long-Term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001 a report from the Children's Oncology Group
    • Salzer WL, Devidas M, Carroll WL, et al. 2010. Long-Term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the Children's Oncology Group. Leukemia 24:355-70
    • (2010) Leukemia , vol.24 , pp. 355-370
    • Salzer, W.L.1    Devidas, M.2    Carroll, W.L.3
  • 75
    • 84921406668 scopus 로고    scopus 로고
    • Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence
    • Lipshultz SE, Franco VI, Sallan SE, et al. 2014. Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: an update of the evidence. Prog. Pediatr. Cardiol. 36:39-49
    • (2014) Prog. Pediatr. Cardiol. , vol.36 , pp. 39-49
    • Lipshultz, S.E.1    Franco, V.I.2    Sallan, S.E.3
  • 76
    • 33947542048 scopus 로고    scopus 로고
    • Dexrazoxane-Associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease
    • Tebbi CK, London WB, Friedman D, et al. 2007. Dexrazoxane-Associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J. Clin. Oncol. 25:493-500
    • (2007) J. Clin. Oncol. , vol.25 , pp. 493-500
    • Tebbi, C.K.1    London, W.B.2    Friedman, D.3
  • 77
    • 84867375691 scopus 로고    scopus 로고
    • Response-dependent and reduced treatment in lower riskHodgkin lymphoma in children and adolescents, results of P9426: A report from the Children's Oncology Group
    • Tebbi CK, Mendenhall NP, London WB, et al. 2012. Response-dependent and reduced treatment in lower riskHodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr. Blood Cancer 59:1259-65
    • (2012) Pediatr. Blood Cancer , vol.59 , pp. 1259-1265
    • Tebbi, C.K.1    Mendenhall, N.P.2    London, W.B.3
  • 78
    • 70349260655 scopus 로고    scopus 로고
    • A risk-Adapted, response-based approach using ABVE-PC for children and adolescents with intermediate-And high-risk Hodgkin lymphoma: The results of P9425
    • Schwartz CL, Constine LS, Villaluna D, et al. 2009. A risk-Adapted, response-based approach using ABVE-PC for children and adolescents with intermediate-And high-risk Hodgkin lymphoma: the results of P9425. Blood 114:2051-59
    • (2009) Blood , vol.114 , pp. 2051-2059
    • Schwartz, C.L.1    Constine, L.S.2    Villaluna, D.3
  • 79
    • 84921355260 scopus 로고    scopus 로고
    • Late mortality and relapse after dexrazoxane (DRZ) treatment: An update from the Children's Oncology Group (COG)
    • Abstr.) Suppl.
    • Chow EJ, Asselin B, Schwartz CL, et al. 2014. Late mortality and relapse after dexrazoxane (DRZ) treatment: an update from the Children's Oncology Group (COG). J. Clin. Oncol. 32(Suppl.):10024 (Abstr.)
    • (2014) J. Clin. Oncol. , vol.32 , pp. 10024
    • Chow, E.J.1    Asselin, B.2    Schwartz, C.L.3
  • 80
    • 84870555288 scopus 로고    scopus 로고
    • Continuous versus bolus infusion of doxorubicin in children with ALL: Long-Term cardiac outcomes
    • Lipshultz SE, Miller TL, Lipsitz SR, et al. 2012. Continuous versus bolus infusion of doxorubicin in children with ALL: long-Term cardiac outcomes. Pediatrics 130:1003-11
    • (2012) Pediatrics , vol.130 , pp. 1003-1011
    • Lipshultz, S.E.1    Miller, T.L.2    Lipsitz, S.R.3
  • 81
    • 1242292932 scopus 로고    scopus 로고
    • Does anthracycline administration by infusion in children affect late cardiotoxicity?. Br
    • Levitt GA, Dorup I, Sorensen K, Sullivan I. 2004. Does anthracycline administration by infusion in children affect late cardiotoxicity?. Br. J. Haematol. 124:463-68
    • (2004) J. Haematol. , vol.124 , pp. 463-468
    • Levitt, G.A.1    Dorup, I.2    Sorensen, K.3    Sullivan, I.4
  • 82
    • 0037410353 scopus 로고    scopus 로고
    • Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers
    • GuptaM, Steinherz PG, Cheung NK, Steinherz L. 2003. Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers. Med. Pediatr. Oncol. 40:343-47
    • (2003) Med. Pediatr. Oncol. , vol.40 , pp. 343-347
    • Gupta, M.1    Steinherz, P.G.2    Cheung, N.K.3    Steinherz, L.4
  • 83
    • 0037087687 scopus 로고    scopus 로고
    • Doxorubicin administration by continuous infusion is not cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol
    • Lipshultz SE, Giantris AL, Lipsitz SR, et al. 2002. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J. Clin. Oncol. 20:1677-82
    • (2002) J. Clin. Oncol. , vol.20 , pp. 1677-1682
    • Lipshultz, S.E.1    Giantris, A.L.2    Lipsitz, S.R.3
  • 84
    • 0025913812 scopus 로고
    • Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
    • SOLVD Investig.
    • SOLVD Investig. 1991. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325:293-302
    • (1991) N. Engl. J. Med. , vol.325 , pp. 293-302
  • 85
    • 0036895164 scopus 로고    scopus 로고
    • Long-Term enalapril therapy for left ventricular dysfunction in doxorubicin-Treated survivors of childhood cancer
    • Lipshultz SE, Lipsitz SR, Sallan SE, et al. 2002. Long-Term enalapril therapy for left ventricular dysfunction in doxorubicin-Treated survivors of childhood cancer. J. Clin. Oncol. 20:4517-22
    • (2002) J. Clin. Oncol. , vol.20 , pp. 4517-4522
    • Lipshultz, S.E.1    Lipsitz, S.R.2    Sallan, S.E.3
  • 86
    • 1542608355 scopus 로고    scopus 로고
    • Enalapril to prevent cardiac function decline in long-Term survivors of pediatric cancer exposed to anthracyclines
    • Silber JH, Cnaan A, Clark BJ, et al. 2004. Enalapril to prevent cardiac function decline in long-Term survivors of pediatric cancer exposed to anthracyclines. J. Clin. Oncol. 22:820-28
    • (2004) J. Clin. Oncol. , vol.22 , pp. 820-828
    • Silber, J.H.1    Cnaan, A.2    Clark, B.J.3
  • 87
    • 33644806519 scopus 로고    scopus 로고
    • Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies
    • Wouters KA, Kremer LC, Miller TL, et al. 2005. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br. J. Haematol. 131:561-78
    • (2005) Br. J. Haematol. , vol.131 , pp. 561-578
    • Wouters, K.A.1    Kremer, L.C.2    Miller, T.L.3
  • 89
    • 84861779336 scopus 로고    scopus 로고
    • Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: Associations with long-Term echocardiographic outcomes
    • Lipshultz SE, Miller TL, Scully RE, et al. 2012. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-Term echocardiographic outcomes. J. Clin. Oncol. 30:1042-49
    • (2012) J. Clin. Oncol. , vol.30 , pp. 1042-1049
    • Lipshultz, S.E.1    Miller, T.L.2    Scully, R.E.3
  • 90
    • 84878731843 scopus 로고    scopus 로고
    • Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients withmalignant hemopathies: TheOVERCOMEtrial (prevention of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)
    • Bosch X, RoviraM, SitgesM, et al. 2013. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients withmalignant hemopathies: theOVERCOMEtrial (prevention of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J. Am. Coll. Cardiol. 61(23):2355-62
    • (2013) J. Am. Coll. Cardiol. , vol.61 , Issue.23 , pp. 2355-2362
    • Bosch, X.1    Rovira, M.2    Sitges, M.3
  • 91
    • 7044229575 scopus 로고    scopus 로고
    • Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure
    • Sliwa K, Norton GR, Kone N, et al. 2004. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. J. Am. Coll. Cardiol. 44:1825-30
    • (2004) J. Am. Coll. Cardiol. , vol.44 , pp. 1825-1830
    • Sliwa, K.1    Norton, G.R.2    Kone, N.3
  • 93
    • 5144228674 scopus 로고    scopus 로고
    • Pediatric heart transplantation for anthracycline cardiomyopathy: Cancer recurrence is rare
    • Ward KM, Binns H, Chin C, et al. 2004. Pediatric heart transplantation for anthracycline cardiomyopathy: cancer recurrence is rare. J. Heart Lung Transplant. 23:1040-45
    • (2004) J. Heart Lung Transplant. , vol.23 , pp. 1040-1045
    • Ward, K.M.1    Binns, H.2    Chin, C.3
  • 94
    • 22544462786 scopus 로고    scopus 로고
    • Cardiac changes associated with growth hormone therapy among children treated with anthracyclines
    • Lipshultz SE, Vlach SA, Lipsitz SR, et al. 2005. Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics 115:1613-22
    • (2005) Pediatrics , vol.115 , pp. 1613-1622
    • Lipshultz, S.E.1    Vlach, S.A.2    Lipsitz, S.R.3
  • 95
    • 84880389889 scopus 로고    scopus 로고
    • Cardiotoxicity in childhood cancer survivors: A problem with long-Term consequences in need of early detection and prevention
    • Lipshultz SE, Franco VI, Cochran TR. 2013. Cardiotoxicity in childhood cancer survivors: a problem with long-Term consequences in need of early detection and prevention. Pediatr. Blood Cancer 60:1395-96
    • (2013) Pediatr. Blood Cancer , vol.60 , pp. 1395-1396
    • Lipshultz, S.E.1    Franco, V.I.2    Cochran, T.R.3
  • 96
    • 84873733744 scopus 로고    scopus 로고
    • Increasing exercise in long-Term survivors of pediatric cancer and their siblings: Should treatment be a family affair?
    • Steiner R. 2013. Increasing exercise in long-Term survivors of pediatric cancer and their siblings: should treatment be a family affair?. Pediatr. Blood Cancer 60:529-30
    • (2013) Pediatr. Blood Cancer , vol.60 , pp. 529-530
    • Steiner, R.1
  • 97
    • 77955462326 scopus 로고    scopus 로고
    • Characteristics and determinants of adiposity in pediatric cancer survivors
    • Miller TL, Lipsitz SR, Lopez-Mitnik G, et al. 2010. Characteristics and determinants of adiposity in pediatric cancer survivors. Cancer Epidemiol. Biomark. Prev. 19:2013-22
    • (2010) Cancer Epidemiol. Biomark. Prev. , vol.19 , pp. 2013-2022
    • Miller, T.L.1    Lipsitz, S.R.2    Lopez-Mitnik, G.3
  • 98
    • 0030904457 scopus 로고    scopus 로고
    • Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience
    • Krischer JP, Epstein S, Cuthbertson DD, et al. 1997. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J. Clin. Oncol. 15:1544-52
    • (1997) J. Clin. Oncol. , vol.15 , pp. 1544-1552
    • Krischer, J.P.1    Epstein, S.2    Cuthbertson, D.D.3
  • 99
    • 0028989408 scopus 로고
    • Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer
    • Lipshultz SE, Lipsitz SR, Mone SM, et al. 1995. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N. Engl. J. Med. 332:1738-43
    • (1995) N. Engl. J. Med. , vol.332 , pp. 1738-1743
    • Lipshultz, S.E.1    Lipsitz, S.R.2    Mone, S.M.3
  • 100
    • 77955290396 scopus 로고    scopus 로고
    • Cardiac function in 5-year survivors of childhood cancer: A long-Term follow-up study
    • van der Pal HJ, van Dalen EC, Hauptmann M, et al. 2010. Cardiac function in 5-year survivors of childhood cancer: a long-Term follow-up study. Arch. Intern. Med. 170:1247-55
    • (2010) Arch. Intern. Med. , vol.170 , pp. 1247-1255
    • Van Der Pal, H.J.1    Van Dalen, E.C.2    Hauptmann, M.3
  • 101
    • 34250641127 scopus 로고    scopus 로고
    • Anthracycline-induced cardiotoxicity: Course, pathophysiology, prevention and management
    • Barry E, Alvarez JA, Scully RE, et al. 2007. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin. Pharmacother. 8:1039-58
    • (2007) Expert Opin. Pharmacother. , vol.8 , pp. 1039-1058
    • Barry, E.1    Alvarez, J.A.2    Scully, R.E.3
  • 102
    • 0001115439 scopus 로고    scopus 로고
    • Anthracycline-induced cardiotoxicity in children and young adults
    • Giantris A, Abdurrahman L, Hinkle A, et al. 1998. Anthracycline-induced cardiotoxicity in children and young adults. Crit. Rev. Oncol. Hematol. 27:53-68
    • (1998) Crit. Rev. Oncol. Hematol. , vol.27 , pp. 53-68
    • Giantris, A.1    Abdurrahman, L.2    Hinkle, A.3
  • 103
    • 84891822955 scopus 로고    scopus 로고
    • Beta-Adrenergic adaptation in idiopathic dilated cardiomyopathy: Differences between children and adults
    • Lipshultz SE, Wilkinson JD. 2014. Beta-Adrenergic adaptation in idiopathic dilated cardiomyopathy: differences between children and adults. Eur. Heart J. 35:10-12
    • (2014) Eur. Heart J. , vol.35 , pp. 10-12
    • Lipshultz, S.E.1    Wilkinson, J.D.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.